Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870

Journal of Infectious Diseases

Volumn 192, Issue 4, 2005, Pages 580-590

  Hou, Victor C ^a   Koeberling, Oliver ^a   Welsch, Jo Anne ^a   Granoff, Dan M ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; GENOME DERIVED NEISSERIAL ANTIGEN 1870 OUTER MEMBRANE VESICLE MENINGOCOCCUS VACCINE; MENINGOCOCCUS VACCINE; PORIN; PORIN A; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENE OVEREXPRESSION; MEMBRANE VESICLE; MENINGITIS; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; RISK ASSESSMENT; SERUM BACTERICIDAL ACTIVITY; VACCINATION; VACCINE PRODUCTION; WILD TYPE;

ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, BACTERIAL; ANTIBODY AFFINITY; ANTIGENS, BACTERIAL; BACTEREMIA; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL PROTEINS; COMPLEMENT C3; GENE EXPRESSION; HUMANS; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MICE; NEISSERIA MENINGITIDIS; RATS;

EID: 23244453502     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/432102     Document Type: Article

References (37)

1. Jodar L, Feavers I, Salisbury D, Granoff DM. Development of vaccines against meningococcal disease. Lancet 2002; 359:1499-508.
2. Thomas M. Prevention of group B meningococcal disease by vaccination: a difficult task. N Z Med J 2004; 117:111016.
3. Desmond N. Getting to grips with an epidemic. Nurs N Z 2004; 10:2.
4. Baker MG, Martin DR, Kieft CE, Lennon D. A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991-2000. J Paediatr Child Health 2001; 37:S13-9.
5. Tappero JW, Lagos R, Ballesteros AM, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999; 281:1520-7.
6. Sacchi CT, Whitney AM, Popovic T, et al. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998. J Infect Dis 2000; 182:1169-76.
7. Martin D, Cadieux N, Hamel J, Brodeur BR. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J Exp Med 1997; 185:1173-83.
8. Hou VC, Moe GR, Raad Z, Wuorimaa T, Granoff DM. Conformational epitopes recognized by protective anti-neisserial surface protein A antibodies. Infect Immun 2003; 71:6844-9.
9. Pizza M, Scarlato V, Masignani V, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genomesequencing. Science 2000; 287:1816-20.
10. Welsch JA, Rossi R, Comanducci M, Granoff DM. Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J Immunol 2004; 172:5606-15.
11. Masignani V, Comanducci M, Giuliani MM, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003; 197:789-99.
12. Caugant DA, Bovre K, Gaustad P, et al. Multilocus genotypes determined by enzyme electrophoresis of Neisseria menmgiiiifis isolated from patients with systemic disease and from healthy carriers. J Gen Microbiol 1986; 132:641-52.
13. Caugant DA, Bol P, Hoiby EA, Zanen HC, Froholm LO. Clones of serogroup B Neisseria meningitidis causing systemic disease in The Netherlands, 1958-1986. J Infect Dis 1990; 162:867-74.
14. Maiden MC, Bygraves JA, Feil E, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA 1998; 95:3140-5.
15. Pagotto FJ, Salimnia H, Totten PA, Dillon JR. Stable shuttle vectors for Neisseria gonorrhoeae, Haemophihis spp. and other bacteria based on a single origin of replication. Gene 2000; 244:13-9.
16. Moe GR, Zuno-Mitchell P, Hammond SN, Granoff DM. Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains. Infect Immun 2002; 70:6021-31.
17. Moe GR, Tan S, Granoff DM. Differences in surface expression of NspA among Neisseria meningitidis group B strains. Infect Immun 1999; 67:5664-75.
18. Santos GF, Deck RR, Donnelly J, Blackwelder W, Granoff DM. Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol 2001; 8:616-23.
19. Granoff DM, Moe GR, Giuliani MM, et al. A novel mimetic antigen eliciting protective antibody to Neisseria meningitidis. J Immunol 2001; 167:6487-96.
20. Granoff DM, Bartoloni A, Ricci S, et al. Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J Immunol 1998; 160:5028-36.
21. Garcia-Ojeda PA, Monser ME, Rubinstein LJ, Jennings HJ, Stein KE. Murine immune response to Neisseria meningitidis group C capsular polysaccharide: analysis of monoclonal antibodies generated in response to a thymus-independent antigen and a thymus-dependent toxoid conjugate vaccine. Infect Immun 2000; 68:239-46.
22. Welsch JA, Moe GR, Rossi R, Adu-Bobie J, Rappuoli R, Granoff DM. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis 2003; 188:1730-40.
23. Moe GR, Zuno-Mitchell P, Lee SS, Lucas AH, Granoff DM. Functional activity of anti-neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B. Infect Immun 2001; 69:3762-71.
24. Carmenate T, Mesa C, Menendez T, Falcon V, Musacchio A. Recombinant Opc protein from Neisseria meningitidis reconstituted into liposomes elicits opsonic antibodies following immunization. Biotechnol Appl Biochem 2001; 34:63-9.
25. Lehmann AK, Gorringe AR, Reddin KM, West K, Smith I, Halstensen A. Human opsonins induced during meningococcal disease recognize transferrin binding protein complexes. Infect Immun 1999; 67:6526-32.
26. O'Dwyer CA, Reddin K, Martin D, et al. Expression of heterologous antigens in commensal Neisseria spp.: preservation of conformational epitopes with vaccine potential. Infect Immun 2004; 72:6511-8.
27. Giuliani MM, Santini L, Brunelli B, et al. The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infect Immun 2005; 73:1151-60.
28. Milagres LG, Gorla MC, Sacchi CT, Rodrigues MM. Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine. Infect Immun 1998; 66:4755-61.
29. van der Ende A, Hopman CT, Keijzers WC, et al. Outbreak of meningococcal disease caused by PorA-deficient meningococci. J Infect Dis 2003; 187:869-71.
30. van der Ende A, Hopman CT, Zaat S, Essink BB, Berkhout B, Dankert J. Variable expression of class 1 outer membrane protein in Neisseria meningitidis is caused by variation in the spacing between the -10 and -35 regions of the promoter. J Bacteriol 1995; 177:2475-80.
31. van der Ende A, Hopman CT, Dankert J. Multiple mechanisms of phase variation of PorA in Neisseria meningitidis. Infect Immun 2000; 68:6685-90.
32. Jelfs J, Munro R, Wedege E, Caugant DA. Sequence variation in the porA gene of a clone of Neisseria meningitidis during epidemic spread. Clin Diagn Lab Immunol 2000; 7:390-5.
33. Alcala B, Salcedo C, Arreaza L, et al. Antigenic and/or phase variation of PorA protein in non-subtypable Neisseria meningitidis strains isolated in Spain. J Med Microbiol 2004; 53:515-8.
34. Martin SL, Borrow R, van der Ley P, Dawson M, Fox AJ, Cartwright KA. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine. Vaccine 2000; 18:2476-81.
35. Russell JE, Jolley KA, Feavers IM, Maiden MC, Suker J. PorA variable regions of Neisseria meningitidis. Emerg Infect Dis 2004; 10:674-8.
36. Sacchi CT, Lemos AP, Brandt ME, et al. Proposed standardization of Neisseria meningitidis PorA variable-region typing nomenclature. Clin Diagn Lab Immunol 1998; 5:845-55.
37. Comanducci M, Bambini S, Brunelli B, et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 2002; 195:1445-54.